Over the last two years, Piramal Pharma Solutions (PPS) has integrated its drug discovery and commercialization services, while addressing gaps through acquisitions and internal investment, according to the company.
The CDMO’s platform provides integrated solutions for orphan diseases, niche therapies, and fast track medicines.
Mr. Vivek Sharma, CEO, Piramal Pharma Solutions said in a press release, "This platform is a result of the growing interest from our customers on structuring preferred relationships with global leaders such as Piramal who can offer end-to-end solutions, coupled with our desire to collaborate with strategic partners."
PPS has 12 research and development and manufacturing locations across North America, Europe, and Asia.
Its consolidated revenues were more than $1.6bn in FY2018, with around 46% of revenues generated from outside India.
PPS has not responded to a request for comment.